This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2006 Oct 5;355(14):1409-12.

doi: 10.1056/NEJMp068185.

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration

Robert Steinbrook¹

Affiliations

PMID: 17021315
DOI: 10.1056/NEJMp068185

Comment

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration

Robert Steinbrook. N Engl J Med. 2006.

. 2006 Oct 5;355(14):1409-12.

doi: 10.1056/NEJMp068185.

Author

Robert Steinbrook¹

Affiliation

¹ rsteinbrook@attglobal.net

PMID: 17021315
DOI: 10.1056/NEJMp068185

No abstract available

PubMed Disclaimer

Comment on

Ranibizumab for neovascular age-related macular degeneration.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Rosenfeld PJ, et al. N Engl J Med. 2006 Oct 5;355(14):1419-31. doi: 10.1056/NEJMoa054481. N Engl J Med. 2006. PMID: 17021318 Clinical Trial.
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Brown DM, et al. N Engl J Med. 2006 Oct 5;355(14):1432-44. doi: 10.1056/NEJMoa062655. N Engl J Med. 2006. PMID: 17021319 Clinical Trial.

Similar articles

Treatment of exudative age-related macular degeneration: many factors to consider.
Olsen TW. Olsen TW. Am J Ophthalmol. 2007 Aug;144(2):281-3. doi: 10.1016/j.ajo.2007.05.005. Am J Ophthalmol. 2007. PMID: 17659955 Free PMC article. No abstract available.
Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
Chang TS, Kokame G, Casey R, Prenner J, Feiner L, Anderson N. Chang TS, et al. Retina. 2009 Oct;29(9):1235-41. doi: 10.1097/IAE.0b013e3181b20eed. Retina. 2009. PMID: 19934818
Bevacizumab and ranibizumab. Bevacizumab and the inverse postcode lottery.
Harris MJ. Harris MJ. BMJ. 2010 Jul 13;341:c3718. doi: 10.1136/bmj.c3718. BMJ. 2010. PMID: 20627986 No abstract available.
Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
Abouammoh M, Sharma S. Abouammoh M, et al. Curr Opin Ophthalmol. 2011 May;22(3):152-8. doi: 10.1097/ICU.0b013e32834595d0. Curr Opin Ophthalmol. 2011. PMID: 21483262 Review.
Age-related macular degeneration.
Jager RD, Mieler WF, Miller JW. Jager RD, et al. N Engl J Med. 2008 Jun 12;358(24):2606-17. doi: 10.1056/NEJMra0801537. N Engl J Med. 2008. PMID: 18550876 Review. No abstract available.

See all similar articles

Cited by

Encoding and display technologies for combinatorial libraries in drug discovery: The coming of age from biology to therapy.
Fan Y, Feng R, Zhang X, Wang ZL, Xiong F, Zhang S, Zhong ZF, Yu H, Zhang QW, Zhang Z, Wang Y, Li G. Fan Y, et al. Acta Pharm Sin B. 2024 Aug;14(8):3362-3384. doi: 10.1016/j.apsb.2024.04.006. Epub 2024 Apr 10. Acta Pharm Sin B. 2024. PMID: 39220863 Free PMC article. Review.
Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.
Zhu S, Fan S, Tang T, Huang J, Zhou H, Huang C, Chen Y, Qian F. Zhu S, et al. Bioeng Transl Med. 2023 May 4;8(6):e10523. doi: 10.1002/btm2.10523. eCollection 2023 Nov. Bioeng Transl Med. 2023. PMID: 38023710 Free PMC article.
Medicare Part B Spending on Macular Degeneration Treatments Associated With Manufacturer Payments to Ophthalmologists.
Dickson SR, James KE. Dickson SR, et al. JAMA Health Forum. 2023 Sep 1;4(9):e232951. doi: 10.1001/jamahealthforum.2023.2951. JAMA Health Forum. 2023. PMID: 37682553 Free PMC article.
Peptide Nanofiber System for Sustained Delivery of Anti-VEGF Proteins to the Eye Vitreous.
Yaylaci S, Dinç E, Aydın B, Tekinay AB, Guler MO. Yaylaci S, et al. Pharmaceutics. 2023 Apr 18;15(4):1264. doi: 10.3390/pharmaceutics15041264. Pharmaceutics. 2023. PMID: 37111749 Free PMC article.
Treatment of neovascular age-related macular degeneration: insights into drug-switch real-world from the Berlin Macular Registry.
Riemer T, Berndt D, Böker A, Lehmann J, Schrifl U, Rau S, Rübsam A, Joussen AM, Zeitz O. Riemer T, et al. Graefes Arch Clin Exp Ophthalmol. 2023 Jun;261(6):1681-1690. doi: 10.1007/s00417-022-05952-8. Epub 2023 Jan 12. Graefes Arch Clin Exp Ophthalmol. 2023. PMID: 36633668 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information